Haematologica · 2016 · 57 citations · 41 references
MedicineHematologyOncologyChemotherapyHematologic OncologyOncologic Nuclear MedicineChemotherapy In Hematologic MalignanciesHematologic Malignancy TherapyLymphoma ImagingChemotherapy Administration In LymphomaDisease-free Survival AnalysisLymphoma ChemotherapyLymphoma Treatment ResponseRelapsed Diffuse Large B-cell LymphomaRituximab-based Therapy
F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%. Patients received 4 cycles of R-CHOP-14, followed by a centrally-reviewed PET performed at day 17-20 of cycle 4 and assessed according to International Harmonisation Project criteria. Median age of the 151 evaluable patients was 57 years, with 79% stages 3-4, 54% bulk, and 54% International Prognostic Index 3-5. Among the 143 patients undergoing interim PET, 101 (71%) were PET-negative (96 of whom completed R-CHOP), 42 (29%) were PET-positive (32 of whom completed R-ICE and 90Y-ibritumomab tiuxetan-BEAM). At a median follow up of 35 months, the 2-year progression-free survival for PET-positive patients was 67%, a rate similar to that for PET-negative patients treated with R-CHOP-14 (74%, P=0.11); overall survival was 78% and 88% (P=0.11), respectively. In an exploratory analysis, progression-free and overall survival were markedly superior for PET-positive Deauville score 4 versus score 5 (P=0.0002 and P=0.001, respectively). Therefore, diffuse large B-cell lymphoma patients who are PET-positive after 4 cycles of R-CHOP-14 and who switched to R-ICE and 90Y-ibritumomab tiuxetan-BEAM achieved favorable survival outcomes similar to those for PET-negative R-CHOP-14-treated patients. Further studies are warranted to confirm these promising results. (Registered at: ACTRN12609001077257).
41
Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text
Pierre Feugier, Ambro van Hoof, Catherine Sebban et al. · Journal of Clinical Oncology · 2005 · 1.5K citations
Medicine, Hematology, Oncology +13
Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra et al. · Journal of Clinical Oncology · 2007 · 1.3K citations · Full text
Medicine, Nuclear Medicine, Oncology +16
Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations
Medicine, Immunology, Oncology +7